10-Q: Bionano Genomics Reports First Quarter 2024 Results, Announces Cost Savings Plan

Bionano Genomics reports a net loss of $31.4 million for the first quarter of 2024, alongside a restructuring plan aimed at reducing operating expenses.

Summary

• Bionano Genomics reported a net loss of $31.4 million for the three months ended March 31, 2024, compared to a net loss of $37.1 million for the same period in 2023.
• Total revenue increased to $8.8 million, up from $7.4 million in the first quarter of 2023, driven by a 25% increase in product revenue.
• The company's installed base of OGM systems grew to 347 as of March 31, 2024, a 34% increase year-over-year.
• Bionano sold 8,249 flowcells in the first quarter of 2024, a 58% increase compared to the 5,226 flowcells sold in the same period of 2023.
• A cost savings plan was announced in March 2024, targeting a reduction of $35 to $40 million in annualized operating expenses starting in the second half of 2024, including a reduction of approximately 120 employees.
• The company's restructuring efforts resulted in charges of $4.6 million for the quarter ended March 31, 2024.
• As of March 31, 2024, Bionano had $15.8 million in cash and cash equivalents, $12.6 million in short-term investments, and $24.8 million in restricted cash and investments.
• The company has an accumulated deficit of $612.6 million as of March 31, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March 31, 2024, are issued.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there is revenue growth and increased adoption of their technology, the significant net loss, going concern warning, and restructuring costs create a negative outlook. The need for additional capital raises further concern.

Positives

• Product revenue increased by 25% year-over-year, indicating growing demand for Bionano's products.
• The installed base of OGM systems grew by 34%, suggesting increasing market adoption of their technology.
• Flowcell sales increased by 58%, demonstrating higher utilization of their systems.
• The cost savings plan is expected to significantly reduce operating expenses in the second half of 2024.
• The company has taken steps to reduce its operating expenses through restructuring and headcount reductions.

Negatives

• The company reported a net loss of $31.4 million for the quarter, indicating ongoing financial challenges.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has a significant accumulated deficit of $612.6 million.
• The company is phasing out certain clinical service offerings from Bionano Laboratories, which may impact future revenue.
• The company has $24.3 million of Notes outstanding at a fair value of $29.1 million as of March 31, 2024, which may be required to be redeemed at 115% of the principal amount.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funding.
• The company may not be able to secure additional financing in a timely manner or on favorable terms.
• The company's operating losses and negative cash flows are expected to continue for at least the next year.
• The company is subject to risks and uncertainties from adverse geopolitical and macroeconomic developments.
• The company's restructuring initiatives may not achieve the intended cost savings or may disrupt operations.
• The company's reliance on a single contract manufacturer for OGM systems and chip consumables poses a supply chain risk.
• The company's products are currently limited to research use only, which may limit their market potential.
• The company is subject to stringent and evolving data privacy and security laws, which could lead to regulatory actions and financial penalties.
• The company may be required to obtain regulatory clearance or approval for its products if they are used for clinical diagnostic purposes, which could be expensive and time-consuming.
• The company's intellectual property may not be adequately protected, which could reduce its competitive advantage.

Future Outlook

The company expects to continue to incur net losses and negative cash flows for the foreseeable future. Management believes that the net proceeds from recent financings, together with existing cash and short-term investments, will be sufficient to fund operating expenses and capital expenditure requirements into at least the third quarter of 2024. The company anticipates that R&D and SG&A expenses will decrease for the remainder of 2024 as a result of cost savings initiatives. The company expects service and other revenue to decrease over the remainder of 2024 as a result of the decision to phase out certain clinical service offerings from Bionano Laboratories.

Management Comments

• Management has prepared cash flows forecasts which indicate that based on the Company's expected operating losses and negative cash flows, there is substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March 31, 2024, are issued.
• Management's plans to raise additional capital to fulfill its operating and capital requirements for at least 12 months include public or private equity or debt financings.

Industry Context

The report reflects the ongoing challenges faced by companies in the life sciences and genomics sector, including the need to balance growth with cost management and the complexities of navigating regulatory requirements. The company's focus on expanding its installed base and increasing consumable sales aligns with industry trends towards recurring revenue models. The restructuring and cost-cutting measures are indicative of a broader trend in the sector to improve financial performance and achieve profitability.

Comparison to Industry Standards

• Bionano's revenue growth of 18% year-over-year is a positive sign, but it is important to compare this to other companies in the genomics space, such as PacBio and Oxford Nanopore, to assess its relative performance.
• The company's net loss of $31.4 million is significant and highlights the need for further cost reductions and revenue growth to achieve profitability. Companies like Illumina, while much larger, serve as a benchmark for profitability in the genomics industry.
• The 34% growth in the installed base of OGM systems is a positive indicator of market adoption, but it is important to compare this to the growth rates of competing technologies to assess Bionano's competitive position.
• The 58% increase in flowcell sales suggests increasing utilization of Bionano's systems, which is a key driver of recurring revenue. This metric should be compared to consumable sales growth of other companies in the genomics space.
• The company's restructuring plan and cost savings initiatives are similar to actions taken by other companies in the sector to improve financial performance. The success of these initiatives will be critical to Bionano's long-term viability.
• The company's reliance on a single contract manufacturer for OGM systems and chip consumables is a risk that is not uncommon in the industry, but it is important to compare Bionano's supply chain strategy to that of its competitors to assess its vulnerability.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional capital.
• Employees have been impacted by the workforce reduction, with approximately 120 employees being laid off.
• Customers may experience changes in service offerings as Bionano Laboratories phases out certain testing services.
• Suppliers may be affected by the company's restructuring and cost-cutting measures.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company plans to continue to expand its commercial operations and research and development efforts.
• The company will focus on implementing its cost savings plan to reduce operating expenses.
• The company will seek additional funding through public or private equity or debt financings.
• The company will continue to monitor and comply with various applicable guidelines and legal requirements in the jurisdictions in which it operates.

Key Dates

Keywords

Bionano Genomics, Optical Genome Mapping, OGM, Genomics, Financial Results, Restructuring, Cost Savings, Net Loss, Revenue, Installed Base, Flowcells, Liquidity, Going Concern, Debt, Convertible Notes, Workforce Reduction, BioDiscovery, Purigen, VIA Software